Donate during COVID-19
Clinical investigation in the Division of Geographic Medicine and Infectious Diseases is a well-established and growing area of research, representing a wide variety of projects, such as epidemiologic studies, clinical trials, translational research and outcomes and modeling studies. Active areas of inquiry include:
The study of Shiga toxin-producing E. coli (e.g., O157:H7), with the overarching goal of understanding how Shiga toxins cause severe diseases in the human host, such as hemolytic uremic syndrome (HUS). We are using “mini-guts” to better understand how these bacteria and their associated virulence factors affect the host intestinal tract, and to dissect the steps by which Shiga toxin traverses the intestine to gain access to the systemic circulation.
Dr. Helen W. Boucher–Clinical development of anti-infective agents; Staphylococcus aureus bacteremia; antimicrobial utilization.
Dr. Debra Poutsiaka–Infections in critically ill or immunocompromised patients; the gastrointestinal microbiota in health and disease; therapies for SARS-CoV-2 infection
Dr. David R. Snydman–Immunecompromised host, Iron regulation and hepcidin in liver transplantation, microbiota in immune regulation of compromised hosts, C. difficile in compromised hosts and hospitalized patients.
Dr. Geneve Allison–OPAT (Outpatient Antibiotic Therapy) patient outcomes; OPAT guidelines; diabetic foot ulcer guidelines; lymphedema guidelines; hospital readmissions.
Dr. Jose Caro–The role of the Human Papillomavirus in anal cancer progression in people living with HIV.
Dr. Brian Chow–Clinical trials for COVID-19 therapies, vaccines
Dr. Jennifer Chow–Role of iron metabolism in risk for infectious diseases; epidemiology of infections in solid organ transplant recipients; epidemiology of invasive fungal infections in critically ill patients.
Dr. Shira Doron–Antibiotic stewardship; transmission, diagnosis and treatment of hospital-acquired infections; antimicrobial stewardship interventions in long term care.
Dr. Yoav Golan – Hospital acquired infections particularly in the critically ill and immunocompromised patient populations; methicillin-resistant Staphylococcus aureus and antimicrobial resistance; invasive candidiasis; decision and cost effectiveness analysis; predictive modeling of infectious diseases.
Dr. Jeffrey K. Griffiths– Biology and epidemiology of cryptosporidiosis in the United States.
Dr. Michael Jordan–Director Tufts Medical Center and Tufts University COVID-19 Biorepository and Comprehensive Database; single genome sequencing of SARS CoV2 to identify resistance and host immune response; impact of sex and gender on COVID-19 outcomes; surveillance epidemiology; transdisciplinary research methods; emerging infectious diseases; public health policy; HIV drug resistance; HIV-1 subtypes and phylogenetic analysis; Antiretroviral Therapy (ART) optimization in low- and middle-income countries; point-of-care urine drug level testing and impact on ART adherence in low- and middle-income countries.
Dr. Rakhi Teena Kohli’s research interests focus on metabolic complications of HIV infection. She has published on the effect of metformin on insulin resistance and abdominal fat in HIV-infected persons and received a NIH K23 award to examine insulin resistance and body fat changes in HIV-infected persons. Relevant Publications:
Dr. Laura Kogelman has been a site PI for several multinational multi-center HIV clinical trials, and has collaborated on several clinical HIV and Travel Medicine studies, including NIH and NIMH funded projects. HIV research projects have included those looking at tools for medication adherence both for HIV medications as well as PrEP. She has also been part of the teams engaged in COVID-19 treatment protocols. Last 3 publications:
Dr. David Stone–HIV infection in the incarcerated population; HIV infection in substance users; adherence to HIV therapy; HIV and hepatitis C co-infection.
Dr. Ramnath Subbaraman–Reasons for patient losses in the TB care cascade in India, digital technologies to support adherence to TB medications, social determinants of health in urban slum communities in India.
Dr. Cheleste Thorpe– The study of how antibiotic treatments perturb the host intestinal microbiota, and the critical metabolic functions that are lost as a result of these perturbations. I have been particularly interested in how different treatments for C. difficile affect the microbiome, and influence the risk of recurrence. I am also interested in understanding how antibiotic treatments that are highly microbiota-damaging may promote the acquisition of drug-resistant organisms. This project is a collaboration with Dr. Kyongbum Lee at Tufts University in Medford, MA, and Dr. David Snydman in our ID division.
C. difficile epidemiology and antimicrobial resistance: I collaborate with Dr. David Snydman on the epidemiology of C. difficile infection, with specific attention to the monitoring of C. difficile antibiotic resistance patterns, and determining which ribotypes are circulating at a given point in time.
View Dr. Thorpe's full publication list >
Michael Jordan, MD
Rakhi Teena Kohli, MD
Laura Kogelman, MD
David Stone, MD
Helen W. Boucher, MD
Shira Doron, MD
Yoav Golan, MD
Jeffrey K. Griffiths, MD
Debra Poutsiaka, MD
David R. Snydman, MD
Jennifer Chow, MD
Ramnath Subbaraman, MD
Jose Caro, MD
Tine Vindenes, MD
It's time to use a name that is trusted locally and revered nationally.
The one that has been by our side throughout our long journey.
Every person here understands
that we are not just taking care of the child.
We are taking care of the childhood.